Financial
FY2025 revenue €19.63bn (+1.5%); operating margin 9.3%; net income €978.0m.
Net debt €9.20bn.
Fresenius Medical Care
HQ Germany · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: FME.DE
FY2025 revenue €19.63bn (+1.5%); operating margin 9.3%; net income €978.0m.
Net debt €9.20bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | €19.6bn | +1.5% | €1.8bn | €978m | Fresenius Medical Care |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
May 2025: TipRanks reported, from a company disclosure, that Fresenius Medical Care faced US FTC scrutiny over alleged anti-competitive practices alongside DaVita, and labour strikes in California linked to union-busting accusations.
Cyber & information governance
No data breaches or cyber incidents involving Fresenius Medical Care found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Aug 2026: the FDA issued a warning letter over its Ogden, Utah plant, citing inadequate investigation of complaints about leaking peritoneal dialysis solution bags. Delflex solution had been recalled in Apr 2026 over lack of sterility assurance.
Contract performance
Dec 2024: NHS England published an intention to directly award satellite adult dialysis services in Taunton, Yeovil and Frome (total about £12.7m, from Apr 2025) to the incumbent, with Fresenius Medical Care Renal Services (UK) listed as supplier.
Competitors
No competitors linked yet.